Profil bibliographique

Carlos A. Raffo

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

13Publications signalées

2572Citations signalées

0Affiliations récentes

Domaines associés

Lipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular DiseasesDiabetes, Cardiovascular Risks, and LipoproteinsAcute Myocardial Infarction ResearchProtease and Inhibitor Mechanisms

Publications récentes

Accès ouvert 2025 articleOpenAlex

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

Philippe Gabríel Steg, Michael Szarek, J. Wouter Jukema, Deepak L. Bhatt et autres

25 citationsCirculation

Accès ouvert 2024 articleOpenAlex

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

Shaun G. Goodman, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

24 citationsEuropean Heart Journal - Cardiovascular Pharmacotherapy

Accès ouvert 2022 articleOpenAlex

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek, Deepak L. Bhatt et autres

125 citationsCirculation

Accès ouvert 2021 articleOpenAlex

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo, Garen Manvelian et autres

144 citationsJournal of the American College of Cardiology

Accès ouvert 2021 articleOpenAlex

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner, Deepak L. Bhatt et autres

40 citationsDiabetes Care

Accès ouvert 2019 articleOpenAlex

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Deepak L. Bhatt, Philippe Gabríel Steg, Shamir R Mehta, Lawrence A. Leiter et autres

214 citationsThe Lancet

Accès ouvert 2019 articleOpenAlex

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek, Marie T. Baccara‐Dinet et autres

331 citationsThe Lancet Diabetes & Endocrinology

Accès ouvert 2017 articleOpenAlex

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Stuart J. Connolly, John W. Eikelboom, Jackie Bosch, Gilles R. Dagenais et autres

757 citationsThe Lancet

Accès ouvert 2017 articleOpenAlex

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Sonia S. Anand, Jackie Bosch, John W. Eikelboom, Stuart J. Connolly et autres

891 citationsThe Lancet

Accès ouvert 2014 conference-paperOpenAlex

Graduate studies on optoelectronics in Argentina: an experience

Juan Carlos Fernández Fernández, M. T. Garea, Silvia Isaurralde, Liliana I. Perez et autres

0 citationsProceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE

2007 articleOpenAlex

Will the five-year engineering degree survive in Argentina?

Alberto Dams, Carlos Godfrid, Carlos A. Raffo

0 citations

2000 articleOpenAlex

Study of speckle size of light scattered from cylindrical rough surfaces

Ricardo G. Berlasso, Fernando Pérez Quintián, María A. Rebollo, Carlos A. Raffo et autres

21 citationsApplied Optics

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.